| P50 | author | Vincenza Conteduca | Q64495656 |
| | Ugo De Giorgi | Q88923334 |
| | Giuseppe Schepisi | Q90886011 |
| P2093 | author name string | Lorena Rossi | |
| | Alberto Farolfi | |
| | Domenico Barone | |
| | Roberta Gunelli | |
| | Delia De Lisi | |
| | Cecilia Menna | |
| | Filippo Martignano | |
| | Giorgia Ravaglia | |
| | Salvatore Roberto Bellia | |
| P2860 | cites work | Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer | Q24632187 |
| | Safety, activity, and immune correlates of anti-PD-1 antibody in cancer | Q24633070 |
| | A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer | Q25255692 |
| | Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm | Q26747699 |
| | Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy | Q26825053 |
| | Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer | Q82278667 |
| | Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide | Q85644770 |
| | Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial | Q44599299 |
| | Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. | Q46007871 |
| | Intratumoral T but not B lymphocytes are related to clinical outcome in prostate cancer | Q46094220 |
| | Paired High-Content Analysis of Prostate Cancer Cells in Bone Marrow and Blood Characterizes Increased Androgen Receptor Expression in Tumor Cell Clusters | Q46855168 |
| | Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer. | Q52838313 |
| | BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. | Q53189566 |
| | Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Men With Metastatic Castration-Resistant Prostate Cancer | Q60809050 |
| | Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type and BRCA1 loss | Q61626110 |
| | Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer | Q27852185 |
| | Integrative clinical genomics of advanced prostate cancer | Q27853170 |
| | Sipuleucel-T immunotherapy for castration-resistant prostate cancer | Q27860648 |
| | Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 |
| | PD-1 Blockade in Tumors with Mismatch-Repair Deficiency | Q28262647 |
| | Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells | Q33926746 |
| | Neoantigens in cancer immunotherapy. | Q34470074 |
| | Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters | Q34605766 |
| | Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study | Q34614776 |
| | DNA repair mechanisms in cancer development and therapy | Q35531287 |
| | Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial | Q35567212 |
| | Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer. | Q36081801 |
| | Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study | Q36999978 |
| | BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers | Q37002955 |
| | An IKKα-E2F1-BMI1 cascade activated by infiltrating B cells controls prostate regeneration and tumor recurrence | Q37019189 |
| | Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer | Q37038179 |
| | Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer | Q37179254 |
| | Promising novel immunotherapies and combinations for prostate cancer | Q37250456 |
| | Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone. | Q37335554 |
| | Intraprostatic distribution and long-term follow-up after AdV-tk immunotherapy as neoadjuvant to surgery in patients with prostate cancer. | Q37347492 |
| | Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. | Q37435472 |
| | Modeling a lethal prostate cancer variant with small-cell carcinoma features | Q37582049 |
| | Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development | Q37861631 |
| | Neuroendocrine differentiation in prostate cancer: current and emerging therapy strategies | Q38222242 |
| | Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients | Q38374885 |
| | Tumor infiltrating B-cells are increased in prostate cancer tissue | Q38393120 |
| | Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer | Q38814032 |
| | Urothelial Cancer: Inflammatory Mediators and Implications for Immunotherapy. | Q38833996 |
| | Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma. | Q38906250 |
| | Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use. | Q39189394 |
| | Neutrophil-to-lymphocyte ratio predicts PSA response, but not outcomes in patients with castration-resistant prostate cancer treated with docetaxel | Q39250942 |
| | Low serum neutrophil count predicts a positive prostate biopsy | Q40047637 |
| | B-cell-derived lymphotoxin promotes castration-resistant prostate cancer | Q40440899 |
| | A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. | Q40621333 |
| | The role of M1 and M2 macrophages in prostate cancer in relation to extracapsular tumor extension and biochemical recurrence after radical prostatectomy | Q42391707 |
| | Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone | Q44108643 |
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunotherapy | Q1427096 |
| | prostate neoplasm | Q56014511 |
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P577 | publication date | 2017-12-05 | |
| P1433 | published in | International Journal of Molecular Sciences | Q3153277 |
| P1476 | title | Immunotherapy for Prostate Cancer: Where We Are Headed | |
| P478 | volume | 18 | |